참고문헌
- Chinsky JM, Singh R, Ficicioglu C, van Karnebeek CDM, Grompe M, Mitchell G, et al. Diagnosis and treatment of tyrosinemia type I: a US and Canadian consensus group review and recommendations. Genet Med 2017;19.
- Pohorecka M, Biernacka M, Jakubowska-Winecka A, Biernacki M, Kusmierska K, Kowalik A, et al. Behavioral and intellectual functioning in patients with tyrosinemia type I. Pediatr Endocrinol Diabetes Metab 2012;18:96-100.
- van Spronsen FJ, Thomasse Y, Smit GP, Leonard JV, Clayton PT, Fidler V, et al. Hereditary tyrosinemia type I: a new clinical classification with difference in prognosis on dietary treatment. Hepatology 1994;20:1187-91. https://doi.org/10.1002/hep.1840200513
- Hahn SH, Pai KS, Lee KB, Park KH, Kim OH, Hong CH, et al. Acute Tyrosinemia Type 1 in a 5 Month Old Korean Boy. J Korean Pediatr Soc 1996;39:866-72.
- Kim KT, Kim YM, Park SE, Nam SO, Park JH. Two Cases of Acute Form of Tyrosinemia Type I. J Korean Pediatr Soc 2002;45:131-6.
- Cho JH, Shim KJ, Kim SK, Shin SH, Lee KH, Yun HS. A Case of Tyrosinemia Type 1 with Cytomegalovirus Infection. Clin Exp Pediatr 2004;47:111-4.
- Park HD, Lee DH, Choi TY, Lee YK, Kim JW, Ki CS, et al. Clinical, biochemical, and genetic analysis of a Korean neonate with hereditary tyrosinemia type 1. Clin Chem Lab Med 2009;47:930-3.
- Choi HJ, Bang HI, Ki CS, Lee SY, Kim JW, Song J, et al. Two novel FAH gene mutations in a patient with hereditary tyrosinemia type I. Ann Clin Lab Sci 2014;44:317-23.
- Poudrier J, Lettre F, Scriver CR, Larochelle J, Tanguay RM. Different Clinical Forms of Hereditary Tyrosinemia (Type I) in Patients with Identical Genotypes. Molecular Genetics and Metabolism 1998;64:119-25. https://doi.org/10.1006/mgme.1998.2695
- Weinberg AG, Mize CE, Worthen HG. The occurrence of hepatoma in the chronic form of hereditary tyrosinemia. The Journal of Pediatrics 1976;88:434-8. https://doi.org/10.1016/S0022-3476(76)80259-4
- Ozcan HN, Karcaaltincaba M, Pektas E, Sivri HS, Oguz B, Dursun A, et al. Imaging liver nodules in tyrosinemia type-1: A retrospective review of 16 cases in a tertiary pediatric hospital. European Journal of Radiology 2019;116:41-6. https://doi.org/10.1016/j.ejrad.2019.04.016
- Mitchell G, Larochelle J, Lambert M, Michaud J, Grenier A, Ogier H, et al. Neurologic crises in hereditary tyrosinemia. N Engl J Med 1990;322:432-7. https://doi.org/10.1056/NEJM199002153220704
- Masurel-Paulet A, Poggi-Bach J, Rolland MO, Bernard O, Guffon N, Dobbelaere D, et al. NTBC treatment in tyrosinaemia type I: long-term outcome in French patients. J Inherit Metab Dis 2008;31:81-7. https://doi.org/10.1007/s10545-008-0793-1
- Couce ML, Sanchez-Pintos P, Aldamiz-Echevarria L, Vitoria I, Navas V, Martin-Hernandez E, et al. Evolution of tyrosinemia type 1 disease in patients treated with nitisinone in Spain. Medicine (Baltimore) 2019;98:e17303. https://doi.org/10.1097/md.0000000000017303
- van Ginkel WG, Rodenburg IL, Harding CO, Hollak CEM, Heiner-Fokkema MR, van Spronsen FJ. Long-Term Outcomes and Practical Considerations in the Pharmacological Management of Tyrosinemia Type 1. Paediatr Drugs 2019;21:413-26. https://doi.org/10.1007/s40272-019-00364-4
- van Vliet D, van Dam E, van Rijn M, Derks TG, Venema-Liefaard G, Hitzert MM, et al. Infants with Tyrosinemia Type 1: Should phenylalanine be supplemented? JIMD Rep 2015;18:117-24. https://doi.org/10.1007/8904_2014_358
- Hickey RD, Nicolas CT, Allen K, Mao S, Elgilani F, Glorioso J, et al. Autologous Gene and Cell Therapy Provides Safe and Long-Term Curative Therapy in A Large Pig Model of Hereditary Tyrosinemia Type 1. Cell Transplant 2019;28:79-88. https://doi.org/10.1177/0963689718814188
- Kaiser RA, Nicolas CT, Allen KL, Chilton JA, Du Z, Hickey RD, et al. Hepatotoxicity and Toxicology of In Vivo Lentiviral Vector Administration in Healthy and Liver-Injury Mouse Models. Hum Gene Ther Clin Dev 2019;30:57-66.
- Thompson WS, Mondal G, Vanlith CJ, Kaiser RA, Lillegard JB. The future of gene-targeted therapy for hereditary tyrosinemia type 1 as a lead indication among the inborn errors of metabolism. Expert Opinion on Orphan Drugs 2020;8:245-56. https://doi.org/10.1080/21678707.2020.1791082
- Yazici H, Er E, Canda E, Habif S, Ucar S, Coker M. Clinical Features of 29 Patients with Hereditary Tyrosinemia I in Western Turkey. The Journal of Pediatric Research 2018;5.
- Mitchell O, Feldman DM, Diakow M, Sigal SH. The pathophysiology of thrombocytopenia in chronic liver disease. Hepatic medicine : evidence and research 2016;8:39-50.
- Baumann M, Witzke O, Canbay A, Patschan S, Treichel U, Gerken G, et al. Serum C3 complement concentrations correlate with liver function in patients with liver cirrhosis. Hepatogastroenterology 2004;51:1451-3.
- Ministry of Health and Welfare. Maternal and child health service 2020. 2020. p. 192.
- Jun SH, Do Seo J, Lee K, Song J. Measurement of Succinylacetone Using HPLC-Tandem Mass Spectrometry and Establishment of a Cut-off Value. Journal of Laboratory Medicine and Quality Assurance 2018;40:149-54. https://doi.org/10.15263/jlmqa.2018.40.3.149
- Metz TF, Mechtler TP, Merk M, Gottschalk A, Lukacin R, Herkner KR, et al. Evaluation of a novel, commercially available mass spectrometry kit for newborn screening including succinylacetone without hydrazine. Clinica Chimica Acta 2012;413:1259-64. https://doi.org/10.1016/j.cca.2012.04.007
- la Marca G, Malvagia S, Pasquini E, Cavicchi C, Morrone A, Ciani F, et al. Newborn Screening for Tyrosinemia Type I: Further Evidence that Succinylacetone Determination on Blood Spot Is Essential. JIMD Rep 2011;1:107-9. https://doi.org/10.1007/8904_2011_24